Last reviewed · How we verify
NCT05290948
Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions
Phase 2 trial testing intravitreal injection of bevacizumab with acetazolamide tablets in Macular Edema in 57 participants. Status unknown.
1 July 2022
Quick facts
| Lead sponsor | Shahid Beheshti University of Medical Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 57 |
| Start date | 12 March 2022 |
| Primary completion | 1 July 2022 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- intravitreal injection of bevacizumab with acetazolamide tablets — full drug profile →
- intravitreal injection of bevacizumab — full drug profile →
Conditions studied
- Macular Edema — all drugs for Macular Edema →
Sponsor
Shahid Beheshti University of Medical Sciences
Who can join
18 and older, any sex, with Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, which will be performed as a randomized clinical trial, all patients with macular edema with central involvement (central macular thickness greater than 300 μm) and corrected vision less than or equal to 20/40 and better than 20/400 were included in the study. After a thorough eye examination, people are randomly divided into two groups. The first group was treated with intravitreal injection of Bevacizumab in three injections one month apart with receiving oral Acetazolamide tablets of 250 mg twice a day, and the second group was treated with intravitreal injection of Bevacizumab for three Loads are spaced one month apart. Ophthalmologic examinations and corrected visual acuity, as well as macular thickness examination, are repeated with Spectral-domain Optical coherence tomography (SD-OCT) at the beginning of treatment and at the end of the first, second, and third months. At the end of the study, the rate of changes in visual acuity and macular thickness in the eyes in the two groups will be compared and will be statistically analyzed.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Risk Factors and Treatment Strategy for Retinal Vascular Occlusive Diseases.
Terao R, Fujino R, Ahmed T. · · 2022 · cited 29× · PMID 36362567 · DOI 10.3390/jcm11216340 -
Acetazolamide and bevacizumab combination therapy versus bevacizumab monotherapy in macular edema secondary to retinal vein occlusion.
Karimi S, Nikkhah H, Nafisi H, Nouri H, et al · · 2023 · cited 2× · PMID 36739258 · DOI 10.1016/j.jfo.2022.09.025
Verify or expand the search:
- PubMed search for NCT05290948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Macular Edema
Currently open trials in the same condition.
- NCT06962839 — A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema · Phase 2 · recruiting
- NCT06686641 — Incidence of Macular Edema in a Uveitis Population · active not recruiting
- NCT05976139 — Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies · NA · recruiting
- NCT05698329 — Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macula · Phase 1 · active not recruiting
- NCT06595355 — Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin · Phase 2, PHASE3 · recruiting
Other Shahid Beheshti University of Medical Sciences trials
Trials by the same sponsor.
- NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
- NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
- NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
- NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
- NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05290948 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
- Last refreshed: 22 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05290948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing